Paltusotine - Generic Drug Details
✉ Email this page to a colleague
US Patents and Regulatory Information for Paltusotine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-002 | Sep 25, 2025 | RX | Yes | Yes | 10,597,377 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | 9,896,432 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | 11,414,397 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
